Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent for treating rhinorrhea in adults and children aged 6+; U.S. sales reached $63M in May 2025.
L&T Plans Green Hydrogen Plant
Union Bank Slips on Margin Woes
Swiggy Shares Slide on Wider Losses
India Eases Research Rules to Spur Innovation
Mobikwik Fraud Hits Shares, 260M Rupee Loss
Aditya Birla AMC Reports Steady Growth
Omaxe Expands in Madhya Pradesh with Rs. 1,200 Crore Township
News that matters the most ⚡